452 related articles for article (PubMed ID: 16891093)
21. Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis.
Dong MJ; Liu ZF; Zhao K; Ruan LX; Wang GL; Yang SY; Sun F; Luo XG
Nucl Med Commun; 2009 Aug; 30(8):639-50. PubMed ID: 19512954
[TBL] [Abstract][Full Text] [Related]
22. [Diagnostic value of positron emission tomography/computed tomography with fluorine-18 fluordeoxyglucose in patients with differentiated thyroid gland carcinoma, high thyroglobulin serum levels and negative iodine whole body scan].
Yamaga LY; Cunha ML; Wagner J; Thom AF; Daniel MM; Funari MB
Arq Bras Endocrinol Metabol; 2007 Jun; 51(4):581-6. PubMed ID: 17684619
[TBL] [Abstract][Full Text] [Related]
23. FDG-PET in thyroid cancer.
Crippa F; Alessi A; Gerali A; Bombardieri E
Tumori; 2003; 89(5):540-3. PubMed ID: 14870781
[TBL] [Abstract][Full Text] [Related]
24. Clinical and pathological factors related to 18F-FDG-PET positivity in the diagnosis of recurrence and/or metastasis in patients with differentiated thyroid cancer.
Esteva D; Muros MA; Llamas-Elvira JM; Jiménez Alonso J; Villar JM; López de la Torre M; Muros T
Ann Surg Oncol; 2009 Jul; 16(7):2006-13. PubMed ID: 19415387
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of [(124)I]-PET/CT and [(18)F]-FDG-PET/CT for localizing recurrence in patients with differentiated thyroid carcinoma.
Lee J; Nah KY; Kim RM; Oh YJ; An YS; Yoon JK; An GI; Choi TH; Cheon GJ; Soh EY; Chung WY
J Korean Med Sci; 2012 Sep; 27(9):1019-26. PubMed ID: 22969247
[TBL] [Abstract][Full Text] [Related]
26. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
[TBL] [Abstract][Full Text] [Related]
27. Imaging in endocrinology: 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in differentiated thyroid carcinoma: clinical indications and controversies in diagnosis and follow-up.
Salvatori M; Biondi B; Rufini V
Eur J Endocrinol; 2015 Sep; 173(3):R115-30. PubMed ID: 25947140
[TBL] [Abstract][Full Text] [Related]
28. The additive clinical value of 18F-FDG PET/CT in defining the recurrence of disease in patients with differentiated thyroid cancer who have isolated increased antithyroglobulin antibody levels.
Ozkan E; Soydal C; Araz M; Aras G; Ibis E
Clin Nucl Med; 2012 Aug; 37(8):755-8. PubMed ID: 22785502
[TBL] [Abstract][Full Text] [Related]
29. Use of
Wu D; Ylli D; Gomes Lima CJ; Lee W; Burman KD; Wartofsky L; Van Nostrand D
Endocrine; 2018 Oct; 62(1):57-63. PubMed ID: 29797211
[TBL] [Abstract][Full Text] [Related]
30. Clinical utility of 18F-FDG PET/CT concurrent with 131I therapy in intermediate-to-high-risk patients with differentiated thyroid cancer: dual-center experience with 286 patients.
Lee JW; Lee SM; Lee DH; Kim YJ
J Nucl Med; 2013 Aug; 54(8):1230-6. PubMed ID: 23813775
[TBL] [Abstract][Full Text] [Related]
31. Comparison of ⁶⁸Ga-DOTATATE PET-CT, ¹⁸F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma.
Ozkan ZG; Kuyumcu S; Uzum AK; Gecer MF; Ozel S; Aral F; Adalet I
Nucl Med Commun; 2015 Mar; 36(3):242-50. PubMed ID: 25369749
[TBL] [Abstract][Full Text] [Related]
32. Clinical approach in patients with metastatic differentiated thyroid carcinoma and negative 131I whole body scintigraphy: importance of 99mTc MIBI scan combined with high resolution neck ultrasonography.
Casara D; Rubello D; Saladini G; Mazzarotto R; Sotti G; Tomasella G; Pelizzo MR
Tumori; 1999; 85(2):122-7. PubMed ID: 10363078
[TBL] [Abstract][Full Text] [Related]
33. PET imaging in differentiated thyroid cancer: where does it fit and how do we use it?
Hall NC; Kloos RT
Arq Bras Endocrinol Metabol; 2007 Jul; 51(5):793-805. PubMed ID: 17891243
[TBL] [Abstract][Full Text] [Related]
34. Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm?
Dietlein M; Scheidhauer K; Voth E; Theissen P; Schicha H
Nuklearmedizin; 1998 Jan; 37(1):12-7. PubMed ID: 9467164
[TBL] [Abstract][Full Text] [Related]
35. Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy.
Helal BO; Merlet P; Toubert ME; Franc B; Schvartz C; Gauthier-Koelesnikov H; Prigent A; Syrota A
J Nucl Med; 2001 Oct; 42(10):1464-9. PubMed ID: 11585858
[TBL] [Abstract][Full Text] [Related]
36. Comparison of 18FDG-PET with 131iodine and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer.
Grünwald F; Menzel C; Bender H; Palmedo H; Willkomm P; Ruhlmann J; Franckson T; Biersack HJ
Thyroid; 1997 Jun; 7(3):327-35. PubMed ID: 9226199
[TBL] [Abstract][Full Text] [Related]
37. Nuclear medicine approaches in the monitoring of thyroid cancer patients.
Sergieva S; Hadjieva T; Doldurova M; Stefanova S; Dudov A
J BUON; 2006; 11(4):511-8. PubMed ID: 17309186
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness analysis of 18F-FDG PET/CT in detecting suspected recurrence or metastasis in well-differentiated thyroid carcinoma patients with negative diagnostic total body scan in Thailand: a decision analysis.
Khiewvan B; Nopmaneejumruslers C; Pusuwan P; Tuchinda P; Tojinda N; Ubolnuch K
J Med Assoc Thai; 2013 Oct; 96(10):1350-64. PubMed ID: 24350419
[TBL] [Abstract][Full Text] [Related]
39. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy.
Oudoux A; Salaun PY; Bournaud C; Campion L; Ansquer C; Rousseau C; Bardet S; Borson-Chazot F; Vuillez JP; Murat A; Mirallié E; Barbet J; Goldenberg DM; Chatal JF; Kraeber-Bodéré F
J Clin Endocrinol Metab; 2007 Dec; 92(12):4590-7. PubMed ID: 17878252
[TBL] [Abstract][Full Text] [Related]
40. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma.
Szakáll S; Esik O; Bajzik G; Repa I; Dabasi G; Sinkovics I; Agoston P; Trón L
J Nucl Med; 2002 Jan; 43(1):66-71. PubMed ID: 11801705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]